NCT04526899 2026-01-08
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
BioNTech SE
Phase 2 Completed
BioNTech SE
University of Pittsburgh
Palleon Pharmaceuticals, Inc.
Oncovir, Inc.
Regeneron Pharmaceuticals